EG 427
Latest round
- Series C
Last raised
- Sep 2026
Total raised
- $52M
Investors
- 6
About EG 427
Based in Paris, France, and founded in 2019, Cyllene Therapeutics, formerly known as EG 427, is a biotechnology company that engages in the research and development of novel approach in gene therapy called pinpoint gene therapy. In 2019, the company developed its own HSV-1 vector technology and demonstrated preclinical proof of concept in the most frequent kind of neurogenic bladder (urinary bladder dysfunction due to supra-sacral spinal cord injury). EG 427 develops HSV-1-based vectors by using the natural qualities of Herpes Simplex Virus 1 (HSV-1) and, in particular, its capacity to define lifetime latency in peripheral neurons to ensure extremely specific and durable expression of transgenes in patients with severe, chronic, and localized illnesses, beginning with peripheral system problems, allowing physicians to cure bladder cancer.
Who invested in EG 427
6 investors across 2 rounds
See all investors in EG 427
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about EG 427
Who invested in EG 427?
EG 427 has 6 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has EG 427 raised?
EG 427 has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did EG 427 last raise money?
EG 427's most recent round on record is a Series C, in Sep 2026.
What does EG 427 do?
Based in Paris, France, and founded in 2019, Cyllene Therapeutics, formerly known as EG 427, is a biotechnology company that engages in the research and development of novel approach in gene therapy called pinpoint gene therapy.
Where is EG 427 headquartered?
EG 427 is headquartered in Paris, France.
Which VCs invest in companies like EG 427?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at EG 427's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like EG 427? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.